COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis?
Autor: | Oluwatosin Wuraola Akande, Ehimario Uche Igumbor, Kelly Osezele Elimian, Cornelius Ehizokhai Ohonsi, Lilian Nwozor, Okanke Oden, Emmanuel Nsa Ekpenyong, Nnaemeka Ndodo, Ifeanyi F Ike, Magdalene Egede, William Nwachukwu, Amedu M Onoja, Jenson Gawain Fofah, Reuben Ishiaku Azi, Chinwe L Ochu, Ifedayo M Adetifa |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Journal of Global Health. 12 |
ISSN: | 2047-2986 2047-2978 |
Popis: | The “lickety-split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was first sequenced is indeed one of the public health successes of the 21st century. Particularly because an 18-month target was initially considered reasonable, and having achieved this success, a “moonshot” goal to ensure that a vaccine is available within 100 days after the next pandemic pathogen is recognized has been set [1]. |
Databáze: | OpenAIRE |
Externí odkaz: |